The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Ipilimumab produces durable responses in some metastatic melanoma patients. Neutrophil, platelet, and eosinophil to lymphocyte ratios (NLR, PLR, and ELR) may be associated with the immune response in cancer thereby acting as biomarkers of toxicity and efficacy in ipilimumab-treated patients. Data were collected on clinical characteristics and lactate dehydrogenase (LDH), NLR, PLR, and ELR at baseline, post cycle 2 and at the end of treatment for 183 patients treated with ipilimumab between 2008 and 2015 at the Princess Margaret Cancer Centre. Associations between clinical characteristics, LDH, NLR, PLR, and ELR with toxicity or survival outcomes of progression-free (PFS) and overall survival (OS) were assessed using univariable and multivariable analysis. Prognostic models of outcome at each time point were determined. Of the 183 patients included, the median age was 58, 85% had M1c disease, 58% were performance status 1, and 64% received ipilimumab as second line therapy. Median follow up was 7.5 months (range: 0.3-49.5), median PFS was 2.8 months (95% confidence intervals (CI): 2.8-3.2), and median OS was 9.6 months (95% CI: 7.9-13.2). Prognostic factors for OS by multivariable analysis were LDH and NLR at all-time points. Prognostic models using LDH (× 2 upper limit of normal) and NLR 4) differentiated patients into high, moderate, and low risk of death prior to or on ipilimumab treatment (P < 0.0001 for each model). No factors were associated with toxicity. Prognostic models based on NLR and LDH values at baseline and on treatment differentiate patients into good, intermediate, and poor prognostic groups and may be relevant in patient management.
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.|Astrazeneca plc, Melbourn Science Park, DaVinci Building, Melbourn, United Kingdom.
Leila
L
Khoja
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Eshetu G
EG
Atenafu
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Arnoud
A
Templeton
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Ye
Y
Qye
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Mary Anne
MA
Chappell
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Sam
S
Saibil
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
David
D
Hogg
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada.
Marcus O
MO
Butler
Princess Margaret Cancer Centre, 610 University Avenue. M5G2M9, Toronto, Canada. anthony.joshua@uhn.ca.|Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia. anthony.joshua@uhn.ca.
Anthony M
AM
Joshua
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D014408:Biomarkers, Tumor / Q000097:blood / Q000378:metabolism*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000074324:Ipilimumab / Q000008:administration & dosage* / Q000009:adverse effects; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D007958:Leukocyte Count; D018655:Lymphocyte Count; D008297:Male; D008545:Melanoma / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000097:blood / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult; D000096142:Cutaneous Malignant Melanoma
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D000074324:Ipilimumab; D007770:L-Lactate Dehydrogenase
Biomarkers; eosinophil to lymphocyte ratio; immune-related adverse events; ipilimumab; melanoma; neutrophil to lymphocyte ratio; platelet to lymphocyte ratio; toxicity
J Natl Cancer Inst. 2014 May 29;106(6):dju124
24875653
Br J Cancer. 2011 Jun 28;105(1):93-103
21629244
N Engl J Med. 2010 Aug 19;363(8):711-23
20525992
Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12
24793958
Scientifica (Cairo). 2013;2013:857519
24278787
Eur J Cancer. 2015 Sep;51(14):2086-94
26227432
N Engl J Med. 2015 Jul 2;373(1):23-34
26027431
N Engl J Med. 2011 Jun 30;364(26):2517-26
21639810
N Engl J Med. 2015 Jun 25;372(26):2521-32
25891173
Ann Oncol. 2014 Mar;25(3):747-753
24504444
Nature. 2014 Nov 27;515(7528):577-81
25428507
N Engl J Med. 2014 Dec 4;371(23):2189-2199
25409260
Ann Oncol. 2013 Jun;24(6):1697-703
23439861
Immunity. 2016 May 17;44(5):1069-78
27192570
J Clin Oncol. 2015 Jun 10;33(17):1889-94
25667295
Cancer Immunol Immunother. 2013 Jun;62(6):1021-8
23591982
Lancet. 2014 Sep 20;384(9948):1109-17
25034862
Cancer Med. 2016 Oct;5(10):2792-2799
27683208
Cancer Immunol Immunother. 2014 May;63(5):449-58
24609989
Cancer. 2010 Apr 1;116(7):1767-75
20143434
Lancet. 2001 Feb 17;357(9255):539-45
11229684
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
19934295
Br J Dermatol. 2016 Jan;174(1):146-51
26343230
Transpl Int. 2014 Jan;27(1):28-31
24350721
Clin Cancer Res. 2016 Jun 15;22(12):2908-18
26787752
Cancer Invest. 2014 May;32(4):144-9
24484235
Science. 2016 May 6;352(6286):658-60
27151852
Clin Cancer Res. 2016 Oct 1;22(19):4848-4858
27169993
Br J Cancer. 2010 Jan 5;102(1):173-80
19997101
N Engl J Med. 2013 Jul 11;369(2):134-44
23724846
Br J Cancer. 2015 Jun 9;112(12):1904-10
26010413
Clin Cancer Res. 2013 Mar 1;19(5):1225-31
23307859